Eli Lilly has enlisted the help of Sanofi-Aventis in order to market its erectile dysfunction drug Cialis in the USA.

Specifically, the France-headquartered drugmaker has been co-marketing a once-daily formulation of Cialis (tadalafil) which was approved by the US Food and Drug Administration in January. The agency gave the green light to the drug in once-daily oral formulations of 2.5mg and 5mg to be used by men who wish to “attempt sexual activity at anytime between doses”.

At the time of the approval, Lilly said that the new doses of the drug, which is also available in parts of Europe, “may be most appropriate for men with ED who anticipate more frequent sexual activity, eg twice weekly”. Total sales of Cialis in the fourth quarter reached $346.2 million, up 29%, and having Sanofi helping push the product can only help growth.

The two-year collaboration, the financial details of which were not disclosed, started about a fortnight ago.

Bayer's Levitra suitable for men with high cholesterol
Staying with ED drugs, Bayer says that its impotence pill Levitra (vardenafil) could be suitable for use in men with dyslipidaemia, based on data presented at the European Association of Urology Congress in Milan.
The 12-week placebo-controlled study involving about 400 men who were also taking statins, "provides further support that Levitra can successfully treat ED, even in men with a serious underlying condition like high cholesterol," commented Ian Eardley, honorary senior lecturer at St. James University Hospital in Leeds, UK.